Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 2/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.56 |
| ▸ | POLB | P06746 | 3/20 | 0.55 |
| ▸ | MTOR | P42345 | 1/20 | 0.55 |
| ▸ | HPGD | P15428 | 4/20 | 0.53 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.51 |
| ▸ | MEN1 | O00255 | 2/20 | 0.51 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.51 |
| ▸ | GABRP | O00591 | 1/20 | 0.50 |
| ▸ | GABRD | O14764 | 1/20 | 0.50 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.50 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.50 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.50 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.50 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.50 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.50 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.50 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.50 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29414456 | 1.00 | GRM5 (0.56) | GRM5KDM4EPOLBMTORHPGD | |
| SCHEMBL20917639 | 0.90 | KDM4E (0.47) | GRM5KDM4EPOLBMTORHPGD | |
| SCHEMBL29230264 | 0.88 | SMN1; SMN2 (0.50) | GRM5KDM4EMTORHPGDGABRP | |
| SCHEMBL31697636 | 0.88 | SMN1; SMN2 (0.50) | GRM5KDM4EMTORHPGDGABRP | |
| SCHEMBL22112922 | 0.87 | L3MBTL3 (0.61) | MTORHRH3 | |
| SCHEMBL6173203 | 0.85 | HPGD (0.59) | GRM5KDM4EPOLBHPGDALOX15 | |
| SCHEMBL10726108 | 0.84 | HPGD (0.61) | GRM5KDM4EPOLBHPGDALOX15 | |
| SCHEMBL24710405 | 0.84 | HRH3 (0.60) | HRH3 | |
| SCHEMBL18822758 | 0.84 | HRH3 (0.54) | MTORHPGDHRH3GABRPGABRD | |
| SCHEMBL29414467 | 0.84 | HRH3 (0.54) | MTORHPGDHRH3GABRPGABRD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2282995-B1 | DERIVATIVES OF QUINOLINES AND QUINOXALINES AS PROTEIN TYROSINE KINASE INHIBITORS | NOVARTIS AG (CH) | 2015-08-26 | — | — | EP | claimed |
| US-8536175-B2 | Quinoxaline carboxamide derivatives as protein tyrosine kinase inhibitors | NOVARTIS AG (CH) | 2013-09-17 | — | — | US | claimed |
| EP-4265254-A2 | IMIDAZO[4,5-B]PYRIDINE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF INFLAMMATORY DISORDERS | Galapagos N.V. (BE) | 2023-10-25 | — | — | EP | disclosed |
| US-20230310433-A1 | COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF INFLAMMATORY DISORDERS | GALAPAGOS NV (BE) | 2023-10-05 | — | — | US | disclosed |
| US-20230310433-A1 | COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF INFLAMMATORY DISORDERS | GALAPAGOS NV (BE) | 2023-10-05 | — | — | US | disclosed |
| EP-3697784-B1 | IMIDAZO[4,5-B]PYRIDINE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF INFLAMMATORY DISORDERS | GALAPAGOS NV (BE) | 2023-10-04 | — | — | EP | disclosed |
| US-11564923-B2 | Compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders | GALAPAGOS NV (BE) | 2023-01-31 | — | — | US | disclosed |
| WO-2022257568-A1 | AZAINDOLE PYRIMIDINAMINE HETEROCYCLIC COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 中国药科大学 | 2022-12-15 | — | — | WO | disclosed |
| WO-2022257568-A1 | AZAINDOLE PYRIMIDINAMINE HETEROCYCLIC COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 中国药科大学 | 2022-12-15 | — | — | WO | disclosed |
| US-11053238-B2 | Benzimidazole derivatives, preparation methods and uses thereof | BETTA PHARMACEUTICALS CO., LTD. (CN) | 2021-07-06 | — | — | US | disclosed |
| US-11053238-B2 | Benzimidazole derivatives, preparation methods and uses thereof | BETTA PHARMACEUTICALS CO., LTD. (CN) | 2021-07-06 | — | — | US | disclosed |
| WO-2009141386-A1 | DERIVATIVES OF QUINOLINES AND QUINOXALINES AS PROTEIN TYROSINE KINASE INHIBITORS | NOVARTIS AG (CH) | 2009-11-26 | — | — | WO | disclosed |
| US-20090182140-A1 | Alicyclic Heterocyclic Compound | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2009-07-16 | — | — | US | disclosed |
| US-20090182140-A1 | Alicyclic Heterocyclic Compound | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2009-07-16 | — | — | US | disclosed |
| WO-2009053269-A1 | NOVEL KINASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-04-30 | — | — | WO | disclosed |
| US-20090105209-A1 | BTK protein kinase inhibitors | ROCHE PALO ALTO LLC | 2009-04-23 | — | — | US | disclosed |
| US-7514468-B2 | Indolinone derivatives substituted in the 6 position, the preparation thereof and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2009-04-07 | — | — | US | disclosed |
| US-20060194813-A1 | Indolinone derivatives substituted in the 6 position, the preparation thereof and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2006-08-31 | — | — | US | disclosed |
| EP-1527046-A1 | INDOLINE DERIVATIVES SUBSTITUTED IN POSITION 6, PRODUCTION AND USE THEREOF AS MEDICAMENTS | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2005-05-04 | — | — | EP | disclosed |
| WO-2004009546-A1 | INDOLINE DERIVATIVES SUBSTITUTED IN POSITION 6, PRODUCTION AND USE THEREOF AS MEDICAMENTS | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2004-01-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090182140-A1 | Alicyclic Heterocyclic Compound | CCR4, CCR1, HRH4 | GRM5 2167/4885KDM4E 657/4885POLB 3362/4885 |
| US-11053238-B2 | Benzimidazole derivatives, preparation methods and uses thereof | CDK6, CDK4, CDK3 | GRM5 3137/4885KDM4E 568/4885POLB 1737/4885 |
| US-20060194813-A1 | Indolinone derivatives substituted in the 6 position, the preparation thereof and their use as pharmaceutical compositions | KDR, FLT1, EGFR | GRM5 1539/4885KDM4E 1648/4885POLB 4146/4885 |
| US-20090105209-A1 | BTK protein kinase inhibitors | BTK, SYK, LYN | GRM5 4674/4885KDM4E 1225/4885POLB 2273/4885 |
| US-11564923-B2 | Compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders | IL15, IL2, IL33 | GRM5 4854/4885KDM4E 4350/4885POLB 2232/4885 |
| US-20230310433-A1 | COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF INFLAMMATORY DISORDERS | IL15, IL2, IL33 | GRM5 4854/4885KDM4E 4350/4885POLB 2232/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.